Anemia Management in the Cardiorenal Patient: A Nephrological Perspective
Journal of the American Heart Association · 04.03.2025 · 14 (5)
DOI: 10.1161/jaha.124.037363 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American Heart Association, erschienen am 04.03.2025. Verfasst von María Marques Vidas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department Hospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA Madrid Spain. Hauptthemen laut MEDLINE: Cardio-Renal Syndrome, Anemia, Hematinics, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Heart failure (HF) and chronic kidney disease (CKD) frequently coexist, sharing significant overlap in prevalence and pathophysiological mechanisms. This coexistence, termed cardiorenal syndrome (CRS), often leads to anemia, which exacerbates both HF and CKD, thereby increasing morbidity and death. Managing anemia in CRS is complex due to conflicting guidelines and the multifactorial nature of the condition. Anemia in CRS is influenced by factors such as inadequate erythropoietin production, iron deficiency, reduced red blood cell life span, and chronic inflammation, which inhibit iron absorption and mobilization. This interplay of mechanisms worsens anemia, further aggravating HF and CKD. Anemia significantly impacts the prognosis of both HF and CKD, and recent trials have shown that hemoglobin increases, particularly with sodium–glucose cotransporter 2 inhibitors, can improve outcomes in patients with HF and CKD. Iron deficiency is also prevalent in both patients with HF and patients with CKD and is associated with poorer exercise capacity and a higher mortality rate. Guidelines for diagnosing and treating iron deficiency differ between HF and CKD. Furthermore, treatment of anemia in CRS is controversial: While sodium–glucose cotransporter 2 inhibitors and intravenous iron has shown consistent benefits in patients with CRS, normalization of hemoglobin with erythropoiesis‐stimulating agents improves symptoms and quality of life but have not consistently demonstrated cardiovascular benefits. There are no definitive guidelines for anemia management in CRS. Treatment should address HF, CKD, and anemia concurrently. A proposed algorithm includes correcting iron deficiency, initiating sodium–glucose cotransporter 2 inhibitors, and considering erythropoiesis‐stimulating agents if hemoglobin remains
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nephrology Department Hospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA Madrid Spain.
- Medicine Department, Facultad de Medicina Universidad Autónoma de Madrid Madrid Spain.
- Anemia Working Group of the Spanish Society of Nephrology Madrid Spain.
- Cardiology Department Hospital Universitario Puerta de Hierro-Majadahonda Madrid Spain.
- Centro de Investigación Biomédica en Red (CIBER Cardiovascular) Madrid Spain.
- Nephrology Department Hospital Clínico Universitario de Valencia (INCLIVA), Valencia, Universitat de València Valencia Spain.
ORCID-Profile: José Portolés, Marta Cobo, José Luis Gorriz, Aleix Cases
Zitieren
APA
Marques Vidas, M., Portolés, J., Cobo, M., Gorriz, J. L., Nuñez, J., & Cases, A. (2025). Anemia Management in the Cardiorenal Patient: A Nephrological Perspective. Journal of the American Heart Association, 14(5). https://doi.org/10.1161/jaha.124.037363
Vancouver
Marques Vidas M, Portolés J, Cobo M, Gorriz JL, Nuñez J, Cases A. Anemia Management in the Cardiorenal Patient: A Nephrological Perspective. Journal of the American Heart Association. 2025;14(5). doi:10.1161/jaha.124.037363
BibTeX
@article{MarquesVidas2025,
author = {Marques Vidas, María and Portolés, José and Cobo, Marta and Gorriz, José Luis and Nuñez, Julio and Cases, Aleix},
title = {Anemia Management in the Cardiorenal Patient: A Nephrological Perspective},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {5},
doi = {10.1161/jaha.124.037363}
}
EUVIMED